Cetera Advisor Networks LLC lifted its position in Becton Dickinson and Co (NYSE:BDX) by 17.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,089 shares of the medical instruments supplier’s stock after buying an additional 609 shares during the quarter. Cetera Advisor Networks LLC’s holdings in Becton Dickinson and were worth $873,000 at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in the company. Koch Industries Inc. raised its stake in Becton Dickinson and by 45,268.7% in the second quarter. Koch Industries Inc. now owns 1,398,264 shares of the medical instruments supplier’s stock valued at $1,391,000 after purchasing an additional 1,395,182 shares in the last quarter. Janus Henderson Group PLC raised its stake in Becton Dickinson and by 1,265.9% in the second quarter. Janus Henderson Group PLC now owns 1,210,837 shares of the medical instruments supplier’s stock valued at $236,245,000 after purchasing an additional 1,122,191 shares in the last quarter. Atlantic Trust Group LLC raised its stake in Becton Dickinson and by 597.3% in the third quarter. Atlantic Trust Group LLC now owns 451,035 shares of the medical instruments supplier’s stock valued at $88,381,000 after purchasing an additional 386,349 shares in the last quarter. DSM Capital Partners LLC purchased a new stake in Becton Dickinson and in the third quarter valued at approximately $75,155,000. Finally, State Street Corp raised its stake in Becton Dickinson and by 3.5% in the second quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after purchasing an additional 342,873 shares in the last quarter. 75.56% of the stock is currently owned by hedge funds and other institutional investors.
Becton Dickinson and Co (NYSE:BDX) opened at $222.87 on Friday. Becton Dickinson and Co has a 52-week low of $175.66 and a 52-week high of $248.39. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.93 and a current ratio of 1.54. The company has a market cap of $51,130.00, a P/E ratio of 170.13, a price-to-earnings-growth ratio of 1.59 and a beta of 1.12.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 9th will be given a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a yield of 1.35%. The ex-dividend date is Thursday, March 8th. Becton Dickinson and’s payout ratio is currently 229.01%.
In other Becton Dickinson and news, Director Timothy M. Ring sold 269,661 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $217.82, for a total transaction of $58,737,559.02. Following the transaction, the director now directly owns 295,753 shares in the company, valued at $64,420,918.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.00% of the stock is owned by company insiders.
A number of equities research analysts recently weighed in on the stock. Bank of America reaffirmed a “buy” rating and issued a $260.00 target price on shares of Becton Dickinson and in a research note on Friday, January 19th. Zacks Investment Research raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $259.00 target price on the stock in a research note on Friday, January 19th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $260.00 target price (up from $223.00) on shares of Becton Dickinson and in a research note on Tuesday, February 6th. Morgan Stanley raised their target price on shares of Becton Dickinson and from $245.00 to $250.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 7th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $245.00 target price on shares of Becton Dickinson and in a research note on Friday, November 3rd. Four research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $237.27.
COPYRIGHT VIOLATION WARNING: “Becton Dickinson and Co (BDX) Stake Raised by Cetera Advisor Networks LLC” was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://stocknewstimes.com/2018/02/18/becton-dickinson-and-co-bdx-stake-raised-by-cetera-advisor-networks-llc.html.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.